Matthew Weston
Stock Analyst at UBS
(2.81)
# 1,574
Out of 5,182 analysts
6
Total ratings
100%
Success rate
33.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Downgrades: Neutral | n/a | $48.02 | - | 1 | Jan 16, 2026 | |
| DBX Dropbox | Assumes: Sell | $29 → $27 | $23.69 | +13.97% | 1 | Sep 18, 2025 | |
| NVO Novo Nordisk | Downgrades: Neutral | n/a | $40.81 | - | 1 | Aug 5, 2025 | |
| NVS Novartis AG | Downgrades: Neutral | n/a | $152.08 | - | 1 | Feb 13, 2025 | |
| AZN AstraZeneca | Upgrades: Buy | n/a | $201.21 | - | 2 | Feb 13, 2025 |
Sanofi
Jan 16, 2026
Downgrades: Neutral
Price Target: n/a
Current: $48.02
Upside: -
Dropbox
Sep 18, 2025
Assumes: Sell
Price Target: $29 → $27
Current: $23.69
Upside: +13.97%
Novo Nordisk
Aug 5, 2025
Downgrades: Neutral
Price Target: n/a
Current: $40.81
Upside: -
Novartis AG
Feb 13, 2025
Downgrades: Neutral
Price Target: n/a
Current: $152.08
Upside: -
AstraZeneca
Feb 13, 2025
Upgrades: Buy
Price Target: n/a
Current: $201.21
Upside: -